RELMADA THERAPEUTICS, INC. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (RLMD) on September 6, 2023, covering events occurring on September 5, 2023. The Company is a Nevada corporation with its principal executive offices in Coral Gables, Florida, and its common stock trades on the NASDAQ Global Select Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of Eric Schmidt from the Board of Directors, effective immediately on September 5, 2023. Dr. Schmidt served as a Class I director since 2019 and held the roles of Chairman of the Audit Committee and member of the Corporate Governance and Nominating Committee.
Management Commentary and Risks
Management stated that Dr. Schmidt's resignation is not due to any disagreement with the Company, its management, or the Board regarding operations, policies, or practices. The departure is attributed to compliance requirements associated with his new role as a sell-side equity analyst at a Wall Street investment banking firm. The Company expressed appreciation for his contributions.
Key Facts for Investor Verification
- Eric Schmidt resigned from the Board of Directors effective September 5, 2023.
- The resignation creates a vacancy on the Audit Committee (Chairman) and the Corporate Governance and Nominating Committee.
- The departure is voluntary and unrelated to any internal disputes or operational issues.
- The Company has not announced a replacement director in this filing.